Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 2441-2450 of 3414 for cancer

Edit search filters
  1. A Study to Evaluate the Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients

    Rochester, MN

  2. A Study to Assess the MEK Inhibitor Mirdametinib (PD-0325901) in Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study of the Outcomes of Natalizumab plus Standard Steroid Treatment for High Risk Acute Graft-Versus-Host Disease

    Rochester, MN

  4. A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

    Jacksonville, FL

  5. Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)

    Rochester, MN

  6. A Study of Using Mesenchymal Stem Cells Developed from the Patients Own Fat Tissue for Reducing Hemodialysis Arteriovenous Fistula Failure

    Rochester, MN

  7. The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

    Rochester, MN

  8. A Study to Evaluate the Effectiveness and Safety of PANZYGA in Pediatric Patients with Chronic Immune Thrombocytopenia (ITP)

    Rochester, MN

  9. APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

    Rochester, MN

  10. In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells

    Rochester, MN

.

Mayo Clinic Footer